Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTP-543 in moderate to severe alopecia areata
NCT05041803Phase 3Completed
- Start
- Oct 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of deuruxolitinib in alopecia areata. Started Oct 2021; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT05041803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05041803.